Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prestige Consumer Healthcare (PBH) Shares Outstanding (Weighted Average) (2016 - 2025)

Prestige Consumer Healthcare (PBH) has 16 years of Shares Outstanding (Weighted Average) data on record, last reported at $47.9 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) fell 3.68% year-over-year to $47.9 million; the TTM value through Dec 2025 reached $47.9 million, down 3.68%, while the annual FY2025 figure was $49.7 million, 0.12% changed from the prior year.
  • Shares Outstanding (Weighted Average) reached $47.9 million in Q4 2025 per PBH's latest filing, down from $49.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $50.3 million in Q4 2021 and bottomed at $47.9 million in Q4 2025.
  • Average Shares Outstanding (Weighted Average) over 5 years is $49.8 million, with a median of $49.8 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): grew 0.25% in 2022, then decreased 3.68% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $50.3 million in 2021, then dropped by 1.21% to $49.7 million in 2022, then rose by 0.08% to $49.7 million in 2023, then decreased by 0.04% to $49.7 million in 2024, then dropped by 3.68% to $47.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $47.9 million in Q4 2025, $49.0 million in Q3 2025, and $49.5 million in Q2 2025.